Lenalidomide

The mechanism of action of lenalidomide has not been fully characterized; its activity is attributed to anti-neoplastic, immunomodulatory and antiangiogenic properties. Inhibits secretion of pro-inflammatory cytokines and increases the secretion of anti-inflammatory cytokines from the peripheral mononuclear blood cells. Inhibits the growth of Namalwa (human B cell lymphoma) and KG-1(human myeloblastic) cells with deletion of chromosome 5. Inhibits growth of multiple myeloma cells, by inducing cell cycle arrest and apoptosis. Lenalidomide also inhibits the expression of cyclooxygenase-2 (COX-2) in-vitro.

Myelodysplastic Syndromes (MDS):

The recommended starting dose of KABILEN (Lenalidomide Capsules) is 10 mg daily with water.

KABILEN (Lenalidomide Capsules) is indicated for the treatment of patients with transfusion-dependent anemia due to Low- or Intermediate-1-risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.

KABILEN 5 – 30 capsules in a bottle. One bottle and package insert housed in a carton.

KABILEN 10 – 30 capsules in a bottle. One bottle and package insert housed in a carton.

KABILEN 25 – 30 capsules in a bottle. One bottle and package insert housed in a carton.

For Hospital use only